First nine months 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.


No votes yet
 
Related
ROVI REPORTS OPERATING REVENUE GROWTH OF 26% AND EBITDA GROWTH OF 37% Operating revenue increased by 26% to 817.7 million euros...
3 min
21/02/2023
Laboratorios Farmacéuticos ROVI, S.A. (ROVI) informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone...
2 min
16/02/2023
Madrid, 6th February, 2023 This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares....
2 min
06/02/2023